FOLD

The 'Ground Truth' for FOLD is not a growth breakout, but a **Merger Arbitrage** play. The investigation confirms FOLD is in the final stages of a **$4.8 billion acquisition by BioMarin (BMRN)** at **$14.50/share**, with a shareholder vote scheduled for March 3, 2026. The technical signals (Quiet Storm, Steady Climb) are misleadingly bullish; they actually reflect the stock being **pegged** to the deal price ($14.35 vs $14.50 offer), explaining the low volatility and 'divergence' from the macro caution. The 'Alpha Male' relative strength is simply the mathematical floor of an all-cash deal in a volatile market.